Juniper will be attending the 7th Drug Formulation, Solubility & Bioavailability Summit in Boston 26-28 March, 2018. Join us to discuss the latest formulation strategies and predictive technologies to accelerate manufacturing, preclinical R&D and time to market. When over 80% of APIs in development are poorly water-soluble, drug companies must rely increasingly on new formulation
Wednesday 28th March 2018 – Friends House, Euston Road, London Update on Contemporary Paediatrics and Presentation of Output from SPaeDD-UK Project* The Smart Paediatric Drug Development (SPaeDD) initiative co-funded by Innovate UK (the UK’s Innovation Agency) is a cross company and academic centre initiative to accelerate paediatric formulation development. Established in 2014 and focussed on
We’re delighted to confirm that Juniper is attending DCAT Week in New York, the premier business development event for companies engaged in pharmaceutical development and manufacturing and related industries. Contact us to arrange a meeting during DCAT week to discuss your small molecule challenges and find out more about Juniper’s drug formulation development and clinical
Pharmaceutical formulation impacts the bioavailability of a given drug and is therefore one of the key factors in the successful development of a new medicine. However, many of the drugs in the development pipelines often possess poor physico-chemical properties, which make them difficult to formulate using classic approaches and hence require the use of new
Juniper will be attending the “Accelerating Cancer Drug Development – From target to patients” seminar in Alderley Park Conference Centre, Alderley Park, Cheshire. Focusing upon the strengths in the discovery, development and manufacture of cancer medicines in the North of England through to commercialisation (patients), this event will highlight industry, academic and clinical strengths whilst
Carlsberg Conference Centre (Copenhagen, Denmark) With more and more drug candidates being poorly soluble compounds there is an increasing pressure on pharmaceutical scientists to come up with enabling formulations. This creates a tremendous need for relatively simple in vitro tools that are capable of delivering in vivo – relevant results for the prediction of bioavailability.